EFFICACY AND SAFETY OF EMPAGLIFLOZIN COMBINED WITH METFORMIN (JARDIANCE DUO) IN GLYCEMIC CONTROL OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

Authors

  • Valéria Goulart Viana
  • Rafaella Abrantes e Silva
  • Guilherme Diniz Marcelino
  • Hanna Fauzi Abdul Rahim
  • Bruna Gabriela Frizzo Alexandre
  • Nathalia Santos Gonçalves
  • Victor Talles de Melo Fontenelle
  • Lidiana Fortunato Correa
  • Carlos Arthur Marinho da Silva Beltrão
  • Edermeson Roque Malheiro Brandão
  • Júlia Maria Soares da Silva
  • Lia Amaral de Sousa
  • José Severino Campos Neto
  • Flávia Viana Henriques Lôbo Costa
  • Maurício Cavalcante Paixão
  • Marcella de Fátima Lomeu Marinho
  • Júlia Maia Vilela Barros
  • Alexandre dos Santos Vasques
  • Karina Cristina dos Santos
  • Pedro Henrique Pessoa Português de Souza
  • Brenda Emanuelly de Campos Ferreira
  • Nelson Freire Silva Filho

Keywords:

Type 2 Diabetes Mellitus, Empagliflozin, Metformin, Combination Therapy, Integrative Review

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by insulin resistance and progressive β-cell dysfunction, resulting in persistent hyperglycemia. Metformin, the first-line drug for T2DM treatment, is often insufficient to maintain long-term glycemic control, requiring combination therapy with other antihyperglycemic agents. Among the new therapeutic options, empagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, stands out for its additional benefits on body weight, blood pressure, and cardiovascular and renal function. Therefore, this study aimed to analyze scientific evidence published over the last ten years regarding the efficacy and safety of the empagliflozin/metformin combination (Jardiance Duo) in glycemic control of patients with T2DM. This is an integrative literature review conducted in the PubMed, SciELO, ScienceDirect, and Scopus databases, including articles published between 2015 and 2025. A total of 11 studies met the eligibility criteria. The findings showed that the combined therapy promotes significant reductions in glycated hemoglobin (HbA1c), improved glycemic control, and additional metabolic benefits, with a favorable safety profile and low incidence of severe adverse events. In conclusion, the empagliflozin/metformin combination is effective, safe, and cost-effective, representing a promising therapeutic strategy for the management of type 2 diabetes mellitus and aligned with current national and international clinical guidelines.

DOI: https://doi.org/10.56238/sevened2025.037-049

Downloads

Published

2025-12-29

Issue

Contemporary Dialogues in Health Sciences - 2° Edição

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Viana, V. G., Abrantes e Silva, R., Marcelino, G. D., Rahim, H. F. A., Alexandre, B. G. F., Gonçalves, N. S., Fontenelle, V. T. de M., Correa, L. F., Beltrão, C. A. M. da S., Brandão, E. R. M., da Silva, J. M. S., de Sousa, L. A., Campos Neto, J. S., Costa, F. V. H. L., Paixão, M. C., Marinho, M. de F. L., Barros, J. M. V., Vasques, A. dos S., dos Santos, K. C., … Silva Filho, N. F. (2025). EFFICACY AND SAFETY OF EMPAGLIFLOZIN COMBINED WITH METFORMIN (JARDIANCE DUO) IN GLYCEMIC CONTROL OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Seven Editora, 712-724. https://sevenpubl.com.br/editora/article/view/8835